Core Insights - The integration of artificial intelligence in the medical field is revolutionizing healthcare, particularly through targeted therapy, which is reshaping cancer treatment and other major diseases [1][2] - Visionary Holdings is a leading player in the biopharmaceutical sector, focusing on targeted therapy and precision medicine, with significant investments in innovative technologies [3][4] Industry Overview - Targeted therapy is based on molecular biology, effectively targeting diseased cells while minimizing harm to healthy cells, leading to improved treatment outcomes and reduced side effects compared to traditional therapies [2] - The global biopharmaceutical market is expected to exceed $1.5 trillion by 2030, with the precision medicine sector projected to grow at a compound annual growth rate (CAGR) of over 10% [2] Company Strategy - Visionary Holdings is investing in tumor-targeted therapy, gene sequencing, AI-assisted drug development, and liquid biopsy technologies to enhance cancer treatment and early diagnosis [3][4] - The company has made strategic investments in biotech firms to develop third-generation EGFR inhibitors for non-small cell lung cancer, which are currently in global clinical trials [4] - Collaborations with leading biotech firms and AI pharmaceutical companies are focused on developing next-generation anticancer drugs targeting specific gene mutations [5] Future Outlook - The combination of targeted therapy and immunotherapy is anticipated to be a significant trend, with AI integration expected to shorten drug development cycles and reduce costs [6] - Visionary Holdings aims to expand the application of targeted therapy to a broader range of diseases, enhancing patient access to advanced treatments [6]
Visionary Holdings Navigates a New Era of Precision Medicine, Achieving Major Breakthroughs in Targeted Therapy